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SHORT COMMUNICAT ION 
Carti lage chondrolys is  by f ibronectin f ragments  causes c leavage of 
aggrecan at the same site as found in osteoarthr i t ic  cart i lage 
Summary/Introduction 
FIBRONECTIN proteolytic fragments (Fn-fs) have 
very potent cartilage chondrolytic activities 
toward cultured cartilage xplants in vitro [1] and 
when injected into rabbit knee joints [2]. Their 
relevance to cartilage pathology is supported by 
their presence at elevated levels in synovial fluids 
of patients with osteoarthritis and rheumatoid 
arthritis [3, 4]. Their relevance is also supported by 
the discovery that their effects are mediated 
through other factors, thought to have roles in 
cartilage pathology, catabolic cytokines. Cyto- 
kines have been detected in conditioned media of 
Fn-ftreated human cartilage [5] and neutralization 
with antibodies directed toward specific cytokines 
blocks cartilage damage by Fn-fs and induction of 
matrix metalloproteinases (MMPs) [5]. The major 
MMP responsible for cartilage damage appears 
to be MMP-3 (stromelysin-1), since antibodies to 
MMP-3 greatly slow cartilage damage caused by 
the Fn-fs [6, 7] and conditioned media of Fn-f 
treated cartilage contains levels of up to 800 nM of 
active MMP-3 [7]. Since MMPs cleave at the the 
Asn3(*~ 36~ bond* in the interglobular domain of 
aggrecan [8], it would be expected that this 
cleavage would occur in Fn-f treated cartilage as 
well. However, this site is not cleaved in normal 
cartilage aggrecan turnover in vitro and in vivo [9] 
or in adult cartilage explants treated with 
interleukin-1 (IL-1) or retinoic acid [9-11]. In the 
latter cases, cleavage occurs exclusively at 
Glu:~92-Ala 393. Further, the expected N-terminal 
Ala aggrecan fragments are found in human 
synovial fluids of patients with both osteoarthritis 
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[11] and inflammatory joint diseases [12]. Accord- 
ingly, the enzymatic activity that may be respon- 
sible for this has been called 'aggrecanase', but the 
responsible proteinase has not yet been identified 
or isolated. 
Our objective here was to determine whether the 
Fn-fs caused cleavage at the physiologically 
relevant 'aggrecanase' site or at the MMP site 
in bovine cartilage aggrecan. The use of bovine 
cartilage was appropriate since proteoglycan 
synthesis suppression, cartilage proteoglycan 
degradation and release of active MMP-3 occurs to 
similar extents in both bovine and human knee 
cartilage explants [5-7]. We report here that 
cleavage was detected at the aggrecanase ite, as 
well as other sites, but not at the MMP site. Thus, 
these data support a potential physiological role 
for Fn-fs in cartilage pathology in osteoarthritis 
or inflammatory joint disease. The data also 
support he relevance of the use of Fn-fs in animal 
models of knee joint damage as described by us 
earlier [2] as well as in in vitro explant culture 
models [1, 5-7]. 
Methods, Results and Discussion 
Cartilage was treated with a 29-kDa Fn-f, which 
was isolated as described [1] and shown to be free 
of several proteolytic activities as described [6], 
and detectable levels of IL-I~, IL-I~, IL-6 and 
tumor necrosis factor (TNF)-~ [5] and to retain 
activity after treatment with detoxi-Gel (Pierce 
Chemical Co., Rockford, IL, U.S.A.) to remove 
endotoxin. Culturing of bovine articular cartilage 
slices with 100 nM Fn-f in Dulbecco's modified 
Eagle's medium (DMEM) was performed as 
described [1]. After 2 days of treatment ofcartilage 
with the Fn-f, media were removed for analysis of 
aggrecan. During this time, assays of aggrecan 
released into media, by means of the dimethyl- 
methylene blue assay, showed that about 45% 
of the total aggrecan had been degraded and 
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lost from the cultured carti lage. Cart i lage was 
also cultured in the presence of 100 U/ml human 
recombinant  IL- la  (Col laborative Research, Bed- 
ford, MA, U.S.A.) for 4 days in DMEM, which was 
supplemented as described previously [10]. During 
this time, the rate of loss of aggrecan from the 
explants increased threefold over that  of control 
cart i lage without cytokine. 
For all cultures, aggrecan was purified from the 
media as described elsewhere [10]. Briefly, the 
condit ioned media were subjected to CsC1 density 
gradient centrifugation. The aggrecan was then 
deglycosylated enzymically and subjected to 
sodium dodecyl sulfate polyacrylamide gel electro- 
phoresis (SDS/PAGE) in a 2-12% gradient gel. 
The unstained gels were then blotted to ProBlott  
membranes (Perkin Elmer, Applied Biosystems 
Division, Foster City, CA, U.S.A.), and the blots 
were stained with Coomassie blue R-250 to localize 
the protein. The N-terminal  sequence of the 
appropr iate band was determined by using an 
Applied Biosystems model 477A protein sequencer 
(operated in the gas phase) with a model 120A 
online high-performance liquid chromatrography 
(HPLC) and PE Nelson (San Jose, CA, U.S.A.) 
Model 2600 chromatography software. 
Bovine aggrecan isolated from Fn-f t reated 
cultures showed on SDS gels, two major bands, 
one of about  200-kDa and one of sl ightly less 
than 200-kDa. Both blotted bands were cut out 
and subjected to amino acid sequencing. The 
lower molecular  weight band showed a sequence 
of ARGSVILXAK (Table I) identical to the 
bovine aggrecan sequence that  had been identified 
previously [10] and that  matched the complete 
bovine precursor sequence (GenBank U76615), 
beginning at residue 393. The pr imary sequence 
showed an initial coupling of 5.2 pmol, with no 
secondary sequence observed above 0.5pmol. 
This sequence matches the ARGSVILTVKPIFEV 
sequence found in the human carti lage-specific 
aggrecan core protein beginning at residue 393* 
[13] (accession umber M55172) with the exception 
of the replacement of Ala for Val in cycle nine. A 
very similar sequence of ARGNVILTAKKP IFDM 
has been reported for the rat  carti lage-specific 
aggrecan core protein precursor  (accession num- 
ber A92623) with the exception of the replacement 
of Asn for Ser in cycle 4 [14]. No residue could be 
identified in cycle 8 of the bovine protein, which is 
*The numbering for the precursor protein is given rather 
than that for the mature protein, the latter of which is often 
cited. For example, the mature protein is 19 residues horter 
than the precursor. Thus, the aggq'ecanase site is Glu392 Alaaga 
in the precursor as used here, rather than GluaTa-AlaaT~ as
typically given for the mature protein. 
Table I 
Phenylthiohydantoin amino acid yield (pmol)* from the 
sequencing of the <200-kDa and 200-kDa fragments 
from Fn-f treated cartilage 
Cycle Residue (< 200-kDa) Residue (200-kDa) 
1 Ala (4.59) 
2 Arg (2.66) 
3 Gly (4.11) 
4 Ser (+)t 
5 Val (2.29) 
6 Ile (1.66) 
7 Leu (2.50) 
8 Xxxw 
9 Ala (2.05) 






*pmol values are background corrected, 
+PTH-Ser was recovered only as the dithiothreitol-dehydroalanine 
adduct at a level equivalent to 1.38 pmol Ser. 
+PTH-Ser was recovered primarily as the dithiothreitol-dehy- 
droalanine adduct at a level equivalent to 1.88 pmol Set. A small 
shoulder near elation of PTH-Ser was observed. 
w is an unidentified residue. 
known to be Thr, an amino acid which is typical ly 
recovered in a low yield. The rapid increase in 
background,  typical for high molecular  weight 
proteins, also complicated the analysis. The 
200-kDa band showed the same N-terminal  c leav-  
age site as the <200-kDa fragment (Table I). The 
pr imary sequence corresponded to an initial 
coupl ing of 7.4 pmol, with no secondary sequence 
observed above 0.5pmol. The sequence was 
terminated after five cycles because the sequence, 
ARGSV, was identical to the sequence described 
above and defined a unique site in the bovine 
aggrecan sequence. The similar sequences for 
the two different size fragments suggests either 
carboxyl-terminal  heterogeneity or var iat ion in 
amount  of glycosylation. 
Since the Fn-f operates through catabol ic 
cytokines, including IL-1 [5], and IL-lc~ t reatment  
of cart i lage has been reported to cause cleavage 
at the aggrecanase site [10], we attempted to 
determine if IL- I~ would generate the same 
cleavage as did the Fn-f. The major  f ragment 
isolated from IL-I~ treated cart i lage was about  
200-kDa on the SDS gel and this yielded a mixture 
of three sequences (Table II). The pr imary 
sequence, with an init ial coupling of 4 pmol, had 
the same amino-terminal  sequence as described 
above for the aggrecanase cleavage product. 
Cleavage at this site was also consistent with 
the molecular  weight of the band. As shown 
earlier, the residue in cycle 8 could not be 
identified, nor could the residue in cycle 14. 
A secondary sequence, (R)AXAFPXV, was 
identified at a lower coupling of only 1.9 pmol. This 
sequence was found to match the bovine carti lage- 
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Phenylthiohydantoin 
Table II 
amino acid yield (pmol)* from the sequencing of the 200-kDa 
fragment from IL-la treated cartilage 
Cycle Primary sequence Secondary sequence Tertiary sequence 
1 (Ala)t (4.12) Arg (1.55) (Gly) (6.39) 
2 (Arg) (0.97) Ala (1.69) (Ser) (0.52) 
3 Gly (3.25) Xxxw Val (0.80) 
4 (Ser) (+)$ Ala (1.37) Ile (1.03) 
5 Val (1.66) Phe (1.41) Leu (1.10) 
6 Ile (1.47) Pro (1.63) Xxxt 
7 Leu (1.35) Xxxt (Ala) (0.67) 
8 Xxxt Val (1.13) Lys (0.69) 
9 Ala (1.29) Pro (0.74) 
10 Lys (0.91) Xxxt 
11 Pro (1.21) Phe (1.00) 
12 Asp (1.03) Xxxt 
13 Phe (0.57) Val (0.61) 
14 Xxxt 
15 Val (0.63) 
*pmol values are background corrected. 
tA residue shown in parentheses is assigned with a lower confidence level. Xxx is an unidentified 
residue. 
:~PTH-Ser was recovered asthe dithiothreitol dehydroalanine adduct at a level equivalent to
0.67 pmol Ser. 
specific aggrecan core protein precursor beginning 
at residue 425. The corresponding human sequence 
is GATAFAEVENETGEA and the rat sequence 
is GTTVFPEAGERTEKT.  Confirmation of this 
cleavage site was found in another exper- 
iment in which this sequence was extended 
as described later. A tert iary sequence, 
(G)(S)VILX(A)KPXFXV, was observed with an 
initial coupling of 1.0 pmol. This is l ikely cleavage 
at residue 395, two residues C-terminal to the 
cleavage site for the primary sequence. The 
observation that IL-I~ treatment of bovine carti- 
lage generated the aggrecanase site is consistent 
with the role of this cytokine in Fn-f-mediated 
carti lage chondrolysis [5]. 
The observation that the aggrecanas e cleavage, 
which occurs in cart i lage in patients with both 
osteoarthrit is and inflammatory joint diseases, as 
well as in IL-lc~ treated carti lage, also occurs 
in Fn-f treated carti lage lends credibil ity to our 
demonstrat ion that  the Fn-fs operate through 
catabolic cytokines and to our proposed physio- 
logic relevance of Fn-fs in carti lage pathology 
in vivo. The paradox that antibodies to MMP-3 
block Fn-f-mediated carti lage chondrolysis [6, 7], 
but that the classical MMP site of cleavage is not 
found in Fn-f treated carti lage, may be because the 
first cleavage of aggrecan is by MMP-3 at bond 
360-361 and subsequent cleavage occurs by the 
unidentif ied 'aggrecanase' or even by MMP-3, at 
bond 392-393. This would result in loss of the 
residue 361-392 peptide and the appearance in 
larger aggrecan fragments of only the aggrecanase 
site sequence beginning with Ala ~93. Such peptides 
with N-terminal Phe 361 have been found by Fosang 
et al. [15] in low buoyant density fractions 
of cesium chloride density gradients of synovial 
fluids of patients with both inflammatory and 
noninf lammatory arthritis. The peptides are a few 
residues shorter than expected, likely due to 
secondary proteolysis from the C-terminal end. 
Nonetheless, their work provides unequivocal 
evidence that MMPs, as well as 'aggrecanase',  act 
directly in aggrecan degradation i arthrit is. Since 
we only analyzed high buoyant density fractions, 
these peptides would not have been detected. 
Further work will be needed to explain the role 
of MMP-3 in Fn-f-mediated carti lage damage, 
nonetheless these data are consistent with the 
possibility that Fn-fs may contr ibute to aggrecan 
degradation in osteoarthrit is and inf lammatory 
joint diseases. These data also support the notion 
that the Fn-fs mediate their effects through 
catabolic cytokines. 
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